Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
View Patent ↗Methods and compositions are provided for prophylaxis and treatment of breast cancer involving administration of a therapeutically effective amount of carbetocin and/or other long-acting oxytocin analogues. 1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin (carbetocin) and/or other long-acting oxytocin analogues are formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to inhibit initiation or growth of breast cancer in the patient. The carbetocin and/or other long-acting oxytocin analogues may also be formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to treat, prevent or alleviate the symptoms of a psychiatric disorder in the patient. Carbetocin may be administered prophylactically or to treat existing conditions in patients by a variety of administration modes, including intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery methods and formulations. Preferably, the carbetocin is administered to a mucosal surface of the patient via intranasal delivery. For this purpose, pharmaceutical compositions are provided for intranasal delivery that incorporate carbetocin in a powder or aqueous formulation for intranasal delivery.
1. A method for treatment of breast cancer in a mammalian patient comprising administering to said patient a therapeutically effective amount of carbetocin in a pharmaceutically acceptable carrier sufficient to inhibit growth of breast cancer in said patient.
2. The method of claim 1 , wherein said carbetocin is administered to said patient by a mode of administration selected from intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery.
3. The method of claim 2 , wherein said carbetocin is administered to said patent intranasally.
4. The method of claim 2 , wherein said carbetocin is formulated in said carrier for intranasal or intrapulmonary administration.
5. The method of claim 4 , wherein said carbetocin is formulated in a powder or aqueous formulation for intranasal delivery.
6. The method of claims 5 , wherein said carbetocin is combined in an aqueous formulation with one or more excipients selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium acetate for intranasal delivery.
7. The method of claim 5 , wherein said carbetocin is formulated with a nonionic surfactant and polysorbate-80 in an aqueous formulation for intranasal delivery.
8. The method of claim 1 , wherein said carbetocin is administered in a dose of at least one microgram.
9. The method of claim 1 , wherein said carbetocin is administered daily in an intranasal formulation.
10. The method of claim 1 , further comprising administering tamoxifen and/or raloxifene to said patient in an amount sufficient to inhibit growth of estrogen-dependent breast cancer in said patient.
11. The method of claim 10 , wherein said carbetocin and said tamoxifen and/or raloxifene are administered simultaneously as a mixture.